Target Price | $270.63 |
Price | $197.59 |
Potential | 36.97% |
Number of Estimates | 27 |
27 Analysts have issued a price target Biogen 2025 . The average Biogen target price is $270.63. This is 36.97% higher than the current stock price. The highest price target is $342.00 73.09% , the lowest is $190.00 3.84% . | |
A rating was issued by 35 analysts: 24 Analysts recommend Biogen to buy, 11 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2025 of 36.97% . Most analysts recommend the Biogen stock at Purchase. |
28 Analysts have issued a sales forecast Biogen 2024 . The average Biogen sales estimate is $9.6b . This is 3.67% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $9.9b 6.93% , the lowest is $9.4b 1.26% .
This results in the following potential growth metrics:
2023 | $9.4b | 0.17% |
---|---|---|
2024 | $9.6b | 2.25% |
2025 | $9.6b | 0.39% |
2026 | $9.8b | 2.14% |
2027 | $10.1b | 3.17% |
2028 | $10.3b | 1.91% |
9 Analysts have issued an Biogen EBITDA forecast 2024. The average Biogen EBITDA estimate is $3.4b . This is 41.49% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 63.96% , the lowest is $2.9b 22.99% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $2.1b | 23.87% |
---|---|---|
2024 | $3.4b | 58.69% |
2025 | $3.6b | 6.17% |
2026 | $3.8b | 6.07% |
2027 | $4.3b | 12.56% |
2028 | $4.9b | 15.29% |
2023 | 22.58% | 23.74% |
---|---|---|
2024 | 35.04% | 55.20% |
2025 | 37.35% | 6.59% |
2026 | 38.78% | 3.83% |
2027 | 42.32% | 9.13% |
2028 | 47.87% | 13.11% |
11 Biogen Analysts have issued a net profit forecast 2024. The average Biogen net profit estimate is $1.8b . This is 56.90% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.2b 90.81% , the lowest is $1.4b 24.56% .
This results in the following potential growth metrics and future Net Margins:
2023 | $1.2b | 61.81% |
---|---|---|
2024 | $1.8b | 56.31% |
2025 | $2.1b | 14.40% |
2026 | $2.5b | 21.04% |
2027 | $2.9b | 13.93% |
2028 | $3.2b | 10.54% |
2023 | 12.33% | 61.74% |
---|---|---|
2024 | 18.85% | 52.86% |
2025 | 21.65% | 14.85% |
2026 | 25.66% | 18.52% |
2027 | 28.33% | 10.41% |
2028 | 30.73% | 8.47% |
11 Analysts have issued a Biogen forecast for earnings per share. The average Biogen <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $12.46 . This is 56.93% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $15.15 90.81% , the lowest is $9.89 24.56% .
This results in the following potential growth metrics and future valuations:
2023 | $7.97 | 61.81% |
---|---|---|
2024 | $12.46 | 56.34% |
2025 | $14.25 | 14.37% |
2026 | $17.25 | 21.05% |
2027 | $19.65 | 13.91% |
2028 | $21.73 | 10.59% |
Current | 24.89 | 83.15% |
---|---|---|
2024 | 15.91 | 36.26% |
2025 | 13.91 | 12.57% |
2026 | 11.49 | 17.40% |
2027 | 10.08 | 12.27% |
2028 | 9.12 | 9.52% |
Based on analysts' sales estimates for 2024, the Biogen stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.51 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.00 .
This results in the following potential growth metrics and future valuations:
Current | 3.63 | 8.10% |
---|---|---|
2024 | 3.51 | 3.52% |
2025 | 3.53 | 0.39% |
2026 | 3.45 | 2.10% |
2027 | 3.35 | 3.07% |
2028 | 3.28 | 1.87% |
Current | 3.10 | 20.48% |
---|---|---|
2024 | 3.00 | 3.54% |
2025 | 3.01 | 0.39% |
2026 | 2.95 | 2.09% |
2027 | 2.86 | 3.07% |
2028 | 2.80 | 1.87% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.